EP300 and metabolic disease: We have previously proposed that a bias in CBP/β-catenin associated transcription at the expense of p300/β-catenin associated transcription with aging fits with epidemiologic data, demonstrating an increased risk of developing cancer, fibrosis, metabolic disease and neurodegeneration [4,84,85].